Usted buscó: brusetabletter (Danés - Inglés)

brusetabletter
effervescent tablets

calcium - sandoz, brusetabletter
calcium-sandoz, brusetabletter

kun til kosttilskud i form af brusetabletter
only food supplements in effervescent tablet form

calcium sandoz brusetabletter bør opbevares utilgængeligt for børn.
calcium sandoz effervescent tablets should be kept out of the reach of children.

calcium sandoz brusetabletter kan indtages med eller uden føde.
calcium sandoz effervescent tablet may be taken with or without food.

brusetablet hvide, cirkulære, flade, med skrå kant forsynede brusetabletter med appelsinduft.
effervescent tablet white, circular, flat faced, bevelled edge effervescent tablets with an orange odour

det bør derfor tillades at anvende dimethylpolysiloxan (e 900) i kosttilskud i form af brusetabletter.
it is therefore appropriate to allow the use of dimethyl polysiloxane (e 900) in food supplements in the form of effervescent tablets.

samlet resume af den faglige vurdering af calcium sandoz brusetabletter (og tilknyttede navne – se bilag 1)
overall summary of the scientific evaluation of calcium sandoz effervescent tablets (and associated names – see anneex 1)

det ekstra indtag, baseret på den nye anvendelse som skumdæmpningsmiddel i kosttilskud i form af brusetabletter, skønnes at være under 10 % af adi.
the additional intake based on the new use as anti-foaming agent in food supplements in the form of effervescent tablets is estimated to be below 10 % of the adi.

kosttilskud i form af brusetabletter indeholder normalt syrer (f.eks. citronsyre) og hydrocarbonat- eller carbonatsalte.
food supplements in the form of effervescent tablets usually contain acids (such as citric acid) and hydrocarbonate or carbonate salts.

lægemidler med højt natriumindhold, f.eks. analgetiske brusetabletter og visse natriumholdige præparater mod dyspepsi, kan også øge koncentrationen af serum-natrium.
medicinal products with high sodium content such as effervescent analgesic preparations and certain sodium containing treatments for dyspepsia may also increase serum sodium concentration.

oral anvendelsefaglige konklusioner og begrundelser for Ændringen af produktresumeet fremlagt af emea9 faglige konklusionersamlet resume af den faglige vurdering af calcium sandoz brusetabletter (og tilknyttede navne ­ se bilag 1)
novartis consumer health uk ltd, wimblehurst road, horsham, west sussex rh12 5ab united kingdom attn:dr jacinta keogh-bennettannex iisandocal 10007ca 1000mgeffervescent tabletsoral usescientific conclusions and grounds for amendment of the summary of product characteristics presented by the emea8 scientific conclusionsoverall summary of the scientific evaluation of calcium sandoz effervescent tablets (and associated names ­ see anneex 1)

calcium sandoz brusetabletter (som indeholder citronsyre) bør anvendes med forsigtighed hos patienter med svær nedsat nyrefunktion, navnlig de, som også behandles med aluminiumholdige lægemidler.
calcium sandoz effervescent tablet (which contains citric acid) should be used with caution in patients with severely impaired renal function, especially those also receiving aluminium-containing preparations.

den 21. april 2005 vedtog chmp en positiv udtalelse, som anbefalede en harmonisering af produktresuméet for calcium sandoz brusetabletter, 500/ 1000 mg og tilknyttede navne til følgende godkendte terapeutiske indikationer:
the chmp issued a positive opinion, on 21 april 2005, recommending the harmonisation of the spc for calcium sandoz effervescent tablets, 500/ 1000 mg and associated names for the following agreed therapeutic indications: -prevention and treatment of calcium deficiency -calcium supplement as an adjunct to specific therapy in the prevention and treatment of osteoporosis -rickets and osteomalacia, in addition to vitamin d3 therapy

calcium sandoz er derfor kontraindiceret hos patienter med overfølsomhed over de aktive indholdsstoffer eller hjælpestofferne i brusetabletterne, sygdomme og/ eller tilstande, der medfører hypercalcæmi og/ eller hypercalcuri; nephrocalcinosis og nephrolithiasis.
calcium sandoz is therefore contraindicated in patients with hypersensitivity to the active substances or to any of the excipients of the effervescent tablet; diseases and/ or conditions resulting in hypercalcaemia and/ or hypercalciuria; nephrocalcinosis and nephrolithiasis.